1. Home
  2. ENTA vs PBYI Comparison

ENTA vs PBYI Comparison

Compare ENTA & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTA
  • PBYI
  • Stock Information
  • Founded
  • ENTA 1995
  • PBYI 2010
  • Country
  • ENTA United States
  • PBYI United States
  • Employees
  • ENTA N/A
  • PBYI N/A
  • Industry
  • ENTA Biotechnology: Pharmaceutical Preparations
  • PBYI Biotechnology: Pharmaceutical Preparations
  • Sector
  • ENTA Health Care
  • PBYI Health Care
  • Exchange
  • ENTA Nasdaq
  • PBYI Nasdaq
  • Market Cap
  • ENTA 127.8M
  • PBYI 153.2M
  • IPO Year
  • ENTA 2013
  • PBYI N/A
  • Fundamental
  • Price
  • ENTA $6.28
  • PBYI $2.80
  • Analyst Decision
  • ENTA Buy
  • PBYI Strong Buy
  • Analyst Count
  • ENTA 4
  • PBYI 1
  • Target Price
  • ENTA $19.50
  • PBYI $7.00
  • AVG Volume (30 Days)
  • ENTA 537.1K
  • PBYI 414.1K
  • Earning Date
  • ENTA 02-05-2025
  • PBYI 11-07-2024
  • Dividend Yield
  • ENTA N/A
  • PBYI N/A
  • EPS Growth
  • ENTA N/A
  • PBYI 492.79
  • EPS
  • ENTA N/A
  • PBYI 0.47
  • Revenue
  • ENTA $67,635,000.00
  • PBYI $243,569,000.00
  • Revenue This Year
  • ENTA $11.80
  • PBYI N/A
  • Revenue Next Year
  • ENTA $3.99
  • PBYI N/A
  • P/E Ratio
  • ENTA N/A
  • PBYI $5.91
  • Revenue Growth
  • ENTA N/A
  • PBYI 6.30
  • 52 Week Low
  • ENTA $5.70
  • PBYI $2.23
  • 52 Week High
  • ENTA $17.80
  • PBYI $7.73
  • Technical
  • Relative Strength Index (RSI)
  • ENTA 31.04
  • PBYI 46.19
  • Support Level
  • ENTA $5.70
  • PBYI $2.72
  • Resistance Level
  • ENTA $6.56
  • PBYI $3.12
  • Average True Range (ATR)
  • ENTA 0.74
  • PBYI 0.19
  • MACD
  • ENTA -0.11
  • PBYI -0.04
  • Stochastic Oscillator
  • ENTA 14.91
  • PBYI 20.48

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Share on Social Networks: